Kalaris Therapeutics Inc
NASDAQ:KLRSBiotechnology
Healthcare
$2.30 +3.52%
+$0.16 today
- Market cap
- $54.75M
- Beta
- 0.14
- P/E (TTM)
- -2.5
- EPS (TTM)
- -$1.86
52W Low $2.14High $11.88
Volume 0.07M
Average 0.08M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$42.98M
FY 2025 · Annual
Investing Cash Flow
-$19.72M
FY 2025 · Annual
Financing Cash Flow
$159.61M
FY 2025 · Annual
+759961.9% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (171.96M) | (15.49M) | (14.7M) | (58.77M) | (43.44M) |
| Depreciation & Amortization | 1.12M | 0 | 0 | 0 | 13K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 271K | 148K | 0 | 0 |
| Change in Working Capital | 19.35M | 3.4M | (1.09M) | (25.31M) | 3.43M |
| Accounts Receivables | 400K | 0 | 0 | 206K | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 20.29M | 1.83M | (402K) | (28.86M) | (88K) |
| Other Working Capital | (1.34M) | 1.57M | (690K) | 3.35M | 3.52M |
| Other Non-Cash Items | 45.17M | 2.04M | 1.51M | 16.37M | (2.98M) |
| Operating Cash Flow | (106.32M) | (9.78M) | (14.13M) | (67.71M) | (42.98M) |
| Capital Expenditures | (26K) | 0 | 0 | 0 | (200K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (76.59M) | 0 | 0 | 0 | (34.52M) |
| Sales of Investments | 262.6M | 0 | 0 | 95M | 15M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 185.98M | 0 | 0 | 95M | (19.72M) |
| Debt Repayment | 0 | 4.3M | 6M | 0 | 7.5M |
| Common Stock Issued | 232K | 0 | 0 | 21K | 50M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 5K | 1.5M | 0 | 102.11M |
| Financing Cash Flow | 232K | 12.78M | 14.24M | 21K | 159.61M |
| Effect of Forex Changes | (896K) | 0 | 0 | 852K | (117.15M) |
| Net Change in Cash | 79M | 3M | 110K | 28.17M | (20.24M) |
| Free Cash Flow | (106.35M) | (9.78M) | (14.13M) | (67.71M) | (43.18M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$43.4M
+ D&A$13.0K
+ Stock-Based Comp$0
+ Deferred Tax$0
+ Working Capital$3.4M
- Other Non-Cash-$3.0M
= Operating Cash Flow-$43.0M
- Capex-$200.0K
= Free Cash Flow-$43.2M
Analysis
FY2025 free cash flow is -$43.2M. FCF conversion is 99.4% of net income. Operating cash flow was -$43.0M, with capex of -$200.0K. The largest bridge item is Working Capital at $3.4M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G | SC 13G filing | Oct 26, 2026 |
Does KLRS generate free cash flow?
Kalaris Therapeutics Inc (KLRS) generated -$43.18M of free cash flow in fiscal 2025.
How much operating cash flow does KLRS produce?
Operating cash flow was -$42.98M, before capital expenditures of $200,000.00.
Continue the stock analysis
Jump to another research area for this company.